Literature DB >> 1650320

The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat.

D K Bosman1, C A van den Buijs, J G de Haan, M A Maas, R A Chamuleau.   

Abstract

Two benzodiazepine-receptor partial inverse agonists (Ro 15-4513, Ro 15-3505) and one benzodiazepine-receptor antagonist (flumazenil) were administered to rats with hepatic encephalopathy due to acute liver ischemia. Significant improvement (P less than 0.002) of both the clinical grade of hepatic encephalopathy and the electroencephalographic abnormalities was observed after administration of the benzodiazepine-receptor partial inverse agonists: comatose rats with no spontaneous righting reflex regained consciousness immediately after injection of the drug. Only slight improvement in clinical hepatic encephalopathy grade was seen after administration of 25 mg/kg of flumazenil. The present data strongly support a role of increased gamma-aminobutyric acid-ergic tone in the pathogenesis of acute hepatic encephalopathy and provide a rationale for trials of benzodiazepine-receptor partial inverse agonists to restore consciousness in hepatic encephalopathy in humans in the near future.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650320     DOI: 10.1016/0016-5085(91)90538-v

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Flumazenil does not affect the increase in rat hippocampal extracellular glutamate concentration produced during thioacetamide-induced hepatic encephalopathy.

Authors:  P McArdle; D H Penning; F Dexter; J D Reynolds
Journal:  Metab Brain Dis       Date:  1996-12       Impact factor: 3.584

Review 2.  Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

3.  An experimental study on somatostatin receptors in the brains of hepatic encephalopathy rats.

Authors:  Z M Zhang; F Z Qiu; X P Chen
Journal:  J Tongji Med Univ       Date:  1994

4.  Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

Authors:  J A Cossar; P C Hayes; R E O'Carroll
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

5.  Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil.

Authors:  H P Meyer; D A Legemate; W van den Brom; J Rothuizen
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

6.  Flumazenil in the treatment of hepatic encephalopathy in children with fulminant liver failure.

Authors:  D Devictor; C Tahiri; C Lanchier; Y Navelet; P Durand; A Rousset
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

7.  Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy.

Authors:  R Gooday; P C Hayes; K Bzeizi; R E O'Carroll
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

8.  Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat.

Authors:  C H Dejong; N E Deutz; P B Soeters
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

Review 9.  Hepatic encephalopathy: a critical current review.

Authors:  Anna Hadjihambi; Natalia Arias; Mohammed Sheikh; Rajiv Jalan
Journal:  Hepatol Int       Date:  2017-08-02       Impact factor: 6.047

Review 10.  The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy.

Authors:  Zefeng Chen; Jingsheng Ruan; Dinghua Li; Min Wang; Zhiwei Han; Wenxia Qiu; Guobin Wu
Journal:  Front Cell Infect Microbiol       Date:  2021-01-21       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.